A Sequencing Platform for Genomic Medicine
Next-generation sequencing (NGS) technologies have revolutionized genomic research over the last decade. With today’s advanced NGS protocols and sequencing instruments, it has become economically feasible to simultaneously sequence billions of DNA or RNA fragments from a single sample. This enables comprehensive studies of genomes and transcriptomes at an unprecedented depth and level of detail.
The Biomedical Sequencing Facility (BSF) is Austria’s first dedicated technology platform for next-generation sequencing in biomedicine. As such, it is positioned to play a catalyzing role in advancing genomic medicine in the country. The BSF offers cutting-edge sequencing technology, expert bioinformatics services, and facilitates access to post-genomic tools for both life science researchers and clinical scientists. In addition, the BSF contributes to several flagship research initiatives that aim to establish proof-of-concept for genomic medicine in Austria.
Christoph Bock
Biosketch
Christoph Bock is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, professor of medical informatics and head of the Institute of Artificial Intelligence at the Medical University of Vienna. Christoph Bock is also scientific coordinator of the Biomedical Sequencing Facility of CeMM and MedUni Vienna, member of the Human Cell Atlas Organizing Committee, fellow of the European Lab for Learning and Intelligent Systems (ELLIS), and elected board member of the Young Academy in the Austrian Academy of Sciences.
He has received important research awards, including an ERC Starting Grant (2016-2021), an ERC Consolidator Grant (2021-2026), the Otto Hahn Medal of the Max Planck Society (2009), the Overton Prize of the International Society for Computational Biology (2017), and the Erwin Schrödinger Prize of the Austrian Academy of Sciences (2022). He has been included in the global list of “Highly Cited Researchers” by Clarivate Analytics (ISI Web of Science) each year since 2019. He co-founded Myllia Biotechnology, a Vienna-based startup company that develops and applies single-cell methods for high-throughput biology and drug discovery.
Michael Schuster
Biosketch
Michael Schuster trained as a biochemist and received his PhD from the University of Vienna in 2003. From 2004 to 2012, he was staff scientist at the EMBL-European Bioinformatics Institute, Cambridge, UK for the Ensembl Genome Browser project led by Ewan Birney. He focused on the systematic quality assessment of automated genome annotation builds that informed decisions throughout build stages for the high-quality and high-information genome assemblies for human, mouse and zebrafish. Since the genomic context revealed further inconsistencies in up-stream data resources, he collaborated with biocurators at the EMBL-EBI, particularly UniProt and the Wellcome Trust Genome Campus on data quality issues.
Michael joined the Biomedical Sequencing Facility (BSF) at CeMM in 2013. As BSF Deputy Head and NGS bioinformatician, he is responsible for the data analysis service of genome, transcriptome and epigenome data sets that the BSF produces for research groups at CeMM, the Medical University of Vienna and the wider scientific community in Austria and Europe.
Contact
Send an e-mail
BSF Website
People
Christoph Bock
